2007-10-01
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Publication
Publication
Breast Cancer Research and Treatment , Volume 105 - Issue 2 p. 221- 228
An early age at first full-term birth is associated with a reduction in the subsequent development of breast cancer among women in the general population. A similar effect has not yet been reported among women who carry an inherited BRCA1 or BRCA2 mutation. We conducted a matched case-control study on 1816 pairs of women with a BRCA1 (n = 1405) or BRCA2 (n = 411) mutation in an attempt to elucidate the relationship between age at first full-term pregnancy and the risk of developing breast cancer. Information about the age at first childbirth and other pregnancy-related variables was derived from a questionnaire administered to women during the course of genetic counselling. There was no difference in the mean age at first full-term birth in the cases and controls (24.9 years vs. 24.8 years; P = 0.81, respectively). Compared to women whose first child was born at or before 18 years of age, a later age at first full-term birth did not influence the risk of developing breast cancer (OR = 1.00 per year; 95% CI 0.98-1.03; P-trend = 0.67). Stratification by mutation status did not affect the results. These findings suggest that an early first full-term birth does not confer protection against breast cancer in BRCA mutation carriers. Nonetheless, BRCA mutation carriers opting for a prophylactic oophorectomy as a breast and/or ovarian cancer risk-reducing strategy should complete childbearing prior to age 40 when this prevention modality is most effective.
| Additional Metadata | |
|---|---|
| , , , , | |
| doi.org/10.1007/s10549-006-9441-3, hdl.handle.net/1765/35723 | |
| Breast Cancer Research and Treatment | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Kotsopoulos, J., Lubinski, J., Lynch, H., Klijn, J., Ghadirian, P., Neuhausen, S., … Bellati, C. (2007). Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 105(2), 221–228. doi:10.1007/s10549-006-9441-3 |
|